Persistent URL of this record https://hdl.handle.net/1887/122668
In Collections
This item can be found in the following collections:
![ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib](https://scholarlypublications.universiteitleiden.nl/sites/all/themes/scholarly/img/closed_access.png)
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib
- All authors
- Thunnissen, E.; Lissenberg-Witte, B.I.; Heuvel, M.M. van den; Monkhorst, K.; Skov, B.G.; Sorensen, J.B.; Mellemgaard, A.; Dingemans, A.M.C.; Speel, E.J.M.; Langen, A.J. de; Hashemi, S.M.S.; Bahce, I.; Drift, M.A. van der; Looijen-Salamon, M.G.; Gosney, J.; Postmus, P.E.; Samii, S.M.S.; Duplaquet, F.; Weynand, B.; Durando, X.; Penault-Llorca, F.; Finn, S.; Grady, A.O.; Oz, B.; Akyurek, N.; Buettner, R.; Wolf, J.; Bubendorf, L.; Duin, S.; Marondel, I.; Heukamp, L.C.; Timens, W.; Schuuring, E.M.D.; Pauwels, P.; Smit, E.F.
- Date
- 2019-12-01
- Journal
- Lung Cancer
- Volume
- 138
- Pages
- 13 - 18